SI-BONE, Inc. reports developments for a medical device business focused on procedural solutions for compromised bone and sacropelvic disorders. The company develops technologies centered on spinopelvic anatomy, including applications in minimally invasive SI joint fusion, adult spinal deformity, spinopelvic and sacropelvic fixation, and pelvic trauma.
Recurring updates include quarterly and annual financial results, revenue guidance, cash flow and adjusted EBITDA commentary, physician adoption metrics, reimbursement developments, and healthcare conference presentations. Product references include the iFuse Implant System, iFuse Bedrock Granite, iFuse TORQ, iFuse TORQ TNT, iFuse 3D, and related surgical implant technologies.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has scheduled its second quarter 2025 financial results announcement for August 4, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET. Investors can access the call through registration and listen to the live webcast on SI-BONE's investor relations website. The webcast recording will remain available for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, announced its participation in the Goldman Sachs 46th Global Healthcare Conference in Miami Beach. The company's management will conduct a fireside chat on June 10, 2025, at 8:20 AM PT/11:20 AM ET. Investors can access the live webcast through registration and the company's website. The webcast recording will be available for replay on SI-BONE's investor relations page for at least 90 days following the event.
SI-BONE Inc (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the 2025 BofA Securities Healthcare Conference in Las Vegas. The company's management will conduct a fireside chat on May 13, 2025, at 8:40 AM PT/11:40 AM ET. Investors can access the live webcast through a registration link or the company's website investor section. The webcast recording will remain available for replay for at least 90 days following the event.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has scheduled its first quarter 2025 financial results announcement for May 5, 2025, after market close. The company will hold a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results.
Investors can participate in the conference call by registering through the provided link. The webcast will be accessible through the company's website's 'Investors' section and will remain available for replay for at least 90 days following the event.
SI-BONE (SIBN) reported strong Q4 2024 financial results with worldwide revenue reaching $49.0 million, up 26% year-over-year. U.S. revenue grew 28% to $46.9 million. The company achieved positive adjusted EBITDA of $1.9 million in Q4, a 139% improvement.
For full-year 2024, worldwide revenue increased 20% to $167.2 million, with U.S. revenue up 21% to $158.4 million. The company reduced its net loss by 29% to $30.9 million. Gross margin remained stable at 79%.
Looking ahead, SI-BONE provided 2025 guidance, projecting worldwide revenue between $193.5-$195.5 million, representing 16-17% growth. The company expects to achieve positive adjusted EBITDA for both second half and full year 2025, with gross margins forecasted at 77-78%.
SI-BONE (SIBN) has announced it will release its fourth quarter and full-year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
Investors can participate in the conference call by registering through the provided link. The webcast will be available on the company's investor relations website and will remain accessible for replay for at least 90 days following the event.
SI-BONE (SIBN) has released preliminary Q4 2024 financial results, showing strong growth across key metrics. The company reported Q4 worldwide revenue between $48.8-$49.0 million, representing approximately 26% growth year-over-year. U.S. revenue reached $46.7-$46.9 million, up about 28%.
For the full year 2024, worldwide revenue was between $167.0-$167.1 million, showing 20% growth, while U.S. revenue reached $158.2-$158.4 million, up 21%. The company expanded its U.S. active physician base to approximately 1,390, representing 23% growth. SI-BONE ended Q4 with approximately $150 million in cash and marketable securities, with net cash use of about $0.8 million in the quarter. Notably, the company achieved adjusted EBITDA profitability in Q4 2024.
SI-BONE (Nasdaq: SIBN), a medical device company focused on sacropelvic disorders, has announced its participation in the Piper Sandler Healthcare Conference in New York. The company's management will conduct a fireside chat on December 4, 2024, at 11:00 a.m. ET / 8:00 a.m. PT.
Investors can access the conference call through a registration link, and the live audio webcast will be available on the company's website's 'Investors' section. The webcast recording will remain accessible for replay for at least 90 days following the event.